Tumor Type | Schedule and Dosea | Tumor Growth Inhibitionb | Mean Tumor Growth Delayc |
---|---|---|---|
% | Days | ||
A375 melanoma | 100 mg/kg Q.D. × 45 days | 65 (P=0.002) | 26.7 ± 7.2 |
50 mg/kg Q.D. × 45 days | 62 (P=0.005) | 13.5 ± 3.1 | |
50 mg/kg b.i.d. × 45 days | 70 (P=0.007) | 23.7 ± 3.2 | |
25 mg/kg b.i.d. × 45 days | 34 (P=0.1) | 12.2 ± 4 | |
12.5 mg/kg b.i.d. × 45 days | 15 (P=0.52) | 2.4 ± 3.4 | |
PC3 prostate carcinoma | 125 mg/kg Q.D. × 40 days | 56 (P=0.01) | 2.3 ± 4 |
100 mg/kg Q.D. × 40 days | 38 (P=0.004) | 8.1 ± 3 | |
50 mg/kg b.i.d. × 40 days | 28 (P=0.16) | 4.4 ± 3.5 | |
A431 epidermoid carcinoma | 125 mg/kg 4on/3off Q.D. × 40 days | 61 (P=0.08) | 21.3 ± 4.8 |
100 mg/kg Q.D. × 40 days | 48 (P=0.07) | 16.6 ± 4.2 | |
50 mg/kg b.i.d. × 40 days | 58 (P=0.05) | 8.8 ± 3.1 | |
MX1 breast carcinoma | 125 mg/kg 4on/3off Q.D. × 40 days | 55 (P=0.004) | 13.2 ± 4.2 |
100 mg/kg Q.D. × 40 days | 41 (P=0.11) | 13.5 ± 4.8 | |
50 mg/kg b.i.d. × 40 days | 30 (P=0.15) | 9.2 ± 3.8 | |
A2780 ovarian carcinoma | 100 mg/kg Q.D. × 30 days | 6.3 (P=0.06) | 1.9 ± 1 |
MV522 lung carcinoma | 100 mg/kg Q.D. × 30 days | 54 (P=0.02) | 9.1 ± 6.8 |
50 mg/kg Q.D. × 30 days | 51 (P=0.06) | 2 ± 6.7 | |
HCT116 colon carcinoma | 100 mg/kg Q.D. × 30 days | 45 (P=0.04) | 13.8 ± 4.4 |
10 mg/kg Q.D. × 30 days | 12 (P=0.14) | 2.2 ± 2.5 |
b.i.d., twice per day; Q.D., once per day; 4on/3off, 4 days of dosing followed by 3 days of rest.